Effects of parathyroid hormone on cancellous bone mass and structure in osteoporosis

Current Pharmaceutical Design

Volumn 10, Issue 21, 2004, Pages 2615-2627

  Miyakoshi, Naohisa ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone formation; Cancellous bone; Osteoporosis; Parathyroid hormone; Trabecular connectivity

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCITRIOL; CALCIUM; ESTROGEN; G PROTEIN COUPLED RECEPTOR; GONADORELIN DERIVATIVE; INSULIN; NANDROLONE; PARATHYROID GLAND HORMONE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PARATHYROID HORMONE[1-38]; PLACEBO; PREDNISOLONE; SOMATOMEDIN C; STREPTOZOCIN; UNCLASSIFIED DRUG;

BONE DENSITY; BONE MASS; BONE MINERAL; BONE STRENGTH; BONE STRUCTURE; BONE TURNOVER; CALCIUM HOMEOSTASIS; CANCELLOUS BONE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG DOSE REGIMEN; DRUG MECHANISM; FRAGILITY FRACTURE; HUMAN; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; VERTEBRA FRACTURE;

ANIMALS; BONE AND BONES; BONE DEVELOPMENT; HUMANS; ORGAN SIZE; OSTEOPOROSIS; PARATHYROID HORMONE;

EID: 3242877412     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383737     Document Type: Review

References (116)

1. Habener JF, Rosenblatt M, Potts JT Jr. Parathyroid hormone: biochemical aspects of biosynthesis, secretion, action, and metabolism. Physiol Rev 1984; 64: 985-1053.
2. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993; 14: 690-709.
3. Christiansen P. The skeleton in primary hyperparathyroidism: a review focusing on bone remodeling, structure, mass, and fracture. APMIS Suppl. 2001; 102: 1-52.
4. Tam CS, Heersche JN, Murray TM, Parsons JA. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 1982; 110: 506-12.
5. Stewart AF. Hyperparathyroidism, humoral hypercalcemia of malignancy, and the anabolic actions of parathyroid hormone and parathyroid hormone-related protein on the skeleton. J Bone Miner Res 2002; 17: 758-62.
6. Bauer W, Aub JC, Albright F. Studies of calcium phosphorus metabolism: a study of the bone trabeculae as a readily available reserve supply of calcium. J Exp Med 1929; 49: 145-62.
7. Kalu DN, Doyle FH, Pennock J, Foster GV. Parathyroid hormone and experimental osteosclerosis. Lancet 1970; 1: 1363-6.
8. Reeve J, Hesp R, Williams D, Hulme P, Klenerman L, Zanelli JM, et al. Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. Lancet 1976; 1: 1035-8.
9. Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OL, Courpron P, et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J 1980; 280: 1340-4.
10. Slovik DM, Rosenthal DI, Doppelt SH, Potts JT Jr, Daly MA, Campbell JA, et al. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1, 25-dihydroxyvitamin D. J Bone Miner Res 1986; 1: 377-81.
11. Hesch RD, Busch U, Prokop M, Delling G, Rittinghaus EF. Increase of vertebral density by combination therapy with pulsatile 1-38hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients. Calcif Tissue Int 1989; 44: 176-80.
12. Reeve J, Davies UM, Hesp R, McNally E, Katz D. Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride. BMJ 1990; 301: 314-8.
13. Bradbeer JN, Arlot ME, Meunier PJ, Reeve J. Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone. Clin Endocrinol 1992; 37: 282-9.
14. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997; 350: 550-5.
15. Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, et al. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 1997; 82: 620-8.
16. Finkelstein JS, Klibanski A, Arnold AL, Toth TL, Hornstein MD, Neer RM. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial. JAMA 1998; 280: 1067-73.
17. Cosman F, Nieves J, Woelfert L, Shen V, Lindsay R. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 1998; 13: 1051-5.
18. Lanc NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998; 102: 1627-33.
19. Fujita T, Inoue T, Morii H, Morita R, Norimatsu H, Orimo H, et al. Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels. Osteoporos Int 1999; 9: 296-306.
20. Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000; 85: 2129-34.
21. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000; 85: 3069-76.
22. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-41.
23. Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001; 16: 925-31.
24. Reeve J, Mitchell A, Tellez M, Hulme P, Green JR, Wardley-Smith B, et al. Treatment with parathyroid peptides and estrogen replacement for severe postmenopausal vertebral osteoporosis: prediction of long-term responses in spine and femur. J Bone Miner Metab 2001; 19: 102-14.
25. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87: 4528-35.
26. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003; 349: 1216-26.
27. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003; 349: 1207-15.
28. Marcus R, Wang O, Satterwhite J, Mitlak B. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003; 18: 18-23.
29. Rehman Q, Lang TF, Arnaud CD, Modin GW, Lane NE. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 2003; 14: 77-81.
30. Orwell ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, et al, The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18: 9-17.
31. Gunness-Hey M, Hock JM. Increased trabecular bone mass in rats treated with human synthetic parathyroid hormone. Metab Bone Dis Relat Res 1984; 5: 177-81.
32. Gera I, Hock JM, Gunness-Hey M, Fonseca J, Raisz LG. Indomethacin does not inhibit the anabolic effect of parathyroid hormone on the long bones of rats. Calcif Tissue Int 1987; 40: 206-11.
33. Ejersted C, Andreassen TT, Hauge EM, Melsen F, Oxlund H. Parathyroid hormone (1-34) increases vertebral bone mass, compressive strength, and quality in old rats. Bone 1995; 17: 507-11.
34. Hock JM, Gera I, Fonseca J, Raisz LG. Human parathyroid hormone-(I-34) increases bone mass in ovariectomized and orchidectomized rats. Endocrinology 1988; 122: 2899-904.
35. Hori M, Uzawa T, Morita K, Noda T, Takahashi H, Inoue J. Effect of human parathyroid hormone (PTH(1-34)) on experimental osteopenia of rats induced by ovariectomy. Bone Miner 1988; 3: 193-9.
36. Tada K, Yamamuro T, Okumura H, Kasai R, Takahashi H. Restoration of axial and appendicular bone volumes by h-PTH(1-34) in parathyroidectomized and osteopenic rats. Bone 1990; 11: 163-9.
37. Liu CC, Kalu DN, Salerno E, Echon R, Hollis BW, Ray M. Preexisting bone loss associated with ovariectomy in rats is reversed by parathyroid hormone. J Bone Miner Res 1991; 6: 1071-80.
38. Shen V, Dempster DW, Mellish RW, Birchman R, Horbert W, Lindsay R. Effects of combined and separate intermittent administration of low-dose human parathyroid hormone fragment (1-34) and 17 beta-estradiol on bone histomorphometry in ovariectomized rats with established osteopenia. Calcif Tissue Int 1992; 50: 214-20.
39. Kimmel DB, Bozzato RP, Kronis KA, Coble T, Sindrey D, Kwong P, et al. The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 1993; 132: 1577-84.
40. Qi H, Li M, Wronski TJ. A comparison of the anabolic effects of parathyroid hormone at skeletal sites with moderate and severe osteopenia in aged ovariectomized rats. J Bone Miner Res 1995; 10: 948-55.
41. Li M, Wronski TJ. Response of femoral neck to estrogen depletion and parathyroid hormone in aged rats. Bone 1995; 16: 551-7.
42. Sato M, Zeng GQ, Turner CH. Biosynthetic human parathyroid hormone (1-34) effects on bone quality in aged ovariectomized rats. Endocrinology 1997; 138: 4330-7.
43. Kneissel M, Boyde A, Gasser JA. Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34). Bone 2001; 28: 237-50.
44. Tsuchida T, Miyakoshi N, Kudo T, Tamura Y, Kasukawa Y, Suzuki K, et al. Restoring effect of human parathyroid hormone (1-34) on trabecular connectivity in ovariectomized rats. Tohoku J Exp Med 2001; 194: 213-21.
45. Sato T, Sato K. The effects of intermittent administration of human parathyroid hormone (1-34) on streptozotocin-induced diabetic rats. J Bone Miner Metab 1997; 15: 145-52.
46. Tsuchida T, Sato K, Miyakoshi N, Abe T, Kudo T, Tamura Y, et al. Histomorphometric evaluation of the recovering effect of human parathyroid hormone (1-34) on bone structure and turnover in streptozotocin-induced diabetic rats. Calcif Tissue Int 2000; 66: 229-33.
47. Suzuki K, Miyakoshi N, Tsuchida T, Kasukawa Y, Sato K, Itoi E. Effects of combined treatment of insulin and human parathyroid hormone(1-34) on cancellous bone mass and structure in streptozotocin-induced diabetic rats. Bone 2003; 33: 108-14.
48. Miyakoshi N. Preventive effects of intermittent administration of human parathyroid hormone on steroid-induced osteopenia in rats. J Orthop Sci 1996; 1: 318-28.
49. Ma YF, Jee WS, Ke HZ, Lin BY, Liang XG, Li M, et al. Human parathyroid hormone-(1-38) restores cancellous bone to the immobilized, osteopenic proximal tibial metaphysis in rats. J Bone Miner Res 1995; 10: 496-505.
50. Kasukawa Y, Miyakoshi N, Itoi E, Tsuchida T, Tamura Y, Kudo T, et al. Effects of h-PTH on cancellous bone mass, connectivity, and bone strength in ovariectomized rats with and without sciatic-neurectomy. J Orthop Res 2004; 22: 457-64.
51. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999; 104: 439-46.
52. Mohan S, Kutilek S, Zhang C, Shen HG, Kodama Y, Srivastava AK, et al. Comparison of bone formation responses to parathyroid hormone(1-34), (1-31), and (2-34) in mice. Bone 2000; 27: 471-8.
53. Zhou H, Iida-Klein A, Lu SS, Ducayen-Knowles M, Levine LR, Dempster DW, et al. Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice. Bone 2003; 32: 513-20.
54. Hirano T, Burr DB, Turner CH, Sato M, Cain RL, Hock JM. Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J Bone Miner Res 1999; 14: 536-45,
55. Malluche HH, Sherman D, Meyer W, Ritz E, Norman AW, Massry SG. Effects of long-term infusion of physiologic doses of 1-34 PTH on bone. Am J Physiol 1982; 242: F197-201.
56. Sato M, Westmore M, Clendenon J, Smith S, Hannum B, Zeng GQ, et al. Three-dimensional modeling of the effects of parathyroid hormone on bone distribution in lumbar vertebrae of ovariectomized cynomolgus macaques. Osteoporos Int 2000; 11: 871-80.
57. Jerome CP, Burr DB, Van Bibber T, Hock JM, Brommage R. Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 2001; 28: 150-9.
58. Kleerekoper M, Villanueva AR, Stanciu J, Rao DS, Parfitt AM. The role of three-dimensional trabecular microstructure in the pathogenesis of vertebral compression fractures. Calcif Tissue Int 1985; 37: 594-7.
59. Mellish RW, Ferguson-Pell MW, Cochran GV, Lindsay R, Dempster DW. A new manual method for assessing two-dimensional cancellous bone structure: comparison between iliac crest and lumbar vertebra. J Bone Miner Res 1991; 6: 689-96.
60. Cummings SR, Black DM, Nevitt MC, Browner WS, Cauley JA, Genant HK, et al. Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group. JAMA 1990; 263: 665-8.
61. Hui SL, Slemenda CW, Johnston CC Jr. The contribution of bone loss to postmenopausal osteoporosis. Osteoporos Int 1990; 1: 30-4.
62. Seeley DG, Browner WS, Nevitt MC, Genant HK, Scott JC, Cummings SR. Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group. Ann Intern Med 1991; 115: 837-42.
63. Melton LJ 3rd, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993; 8: 1227-33.
64. Vesterby A, Mosekilde L, Gundersen HJ, Melsen F, Mosekilde L, Holme K, et al. Biologically meaningful determinants of the in vitro strength of lumbar vertebrae. Bone 1991; 12: 219-24.
65. Chevalier F, Laval-Jeantet AM, Laval-Jeantet M, Berger C. CT image analysis of the vertebral trabecular network in vivo. Calcif Tissue Int 1992; 51: 8-13.
66. Wallach S, Feinblatt JD, Carstens JH Jr, Avioli LV. The bone "quality" problem. Calcif Tissue Int 1992; 51: 169-72.
67. Dalstra M, Huiskes R, Odgaard A, van Erning L. Mechanical and textural properties of pelvic trabecular bone. J Biomech 1993; 26: 523-35.
68. Jiang Y, Zhao J, Augat P, Ouyang X, Lu Y, Majumdar S, et al. Trabecular bone mineral and calculated structure of human bone specimens scanned by peripheral quantitative computed tomography: relation to biomechanical properties. J Bone Miner Res 1998; 13: 1783-90.
69. Kronenberg HM, Lanske B, Kovacs CS, Chung UI, Lee K, Segre GV, et al. Functional analysis of the PTH/PTHrP network of ligands and receptors. Recent Prog Horm Res 1998; 53: 283-301,
70. Lee K, Deeds JD, Chiba S, Un-No M, Bond AT, Segre GV. Parathyroid hormone induces sequential c-fos expression in bone cells in vivo: in situ localization of its receptor and c-fos messenger ribonucleic acids. Endocrinology 1994; 134: 441-50.
71. Onishi T, Zhang W, Cao X, Hruska K. The mitogenic effect of parathyroid hormone is associated with E2F-dependent activation of cyclin-dependent kinase 1 (cdc2) in osteoblast precursors. J Bone Miner Res 1997; 12 : 1596-605.
72. Cole JA. Parathyroid hormone activates mitogen-activated protein kinase in opossum kidney cells. Endocrinology 1999; 140: 5771-9.
73. McCarthy TL, Centrella M, Canalis E. Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast-enriched cultures from fetal rat bone. Endocrinology 1989; 124: 1247-53.
74. Linkhart TA, Mohan S. Parathyroid hormone stimulates release of insulin-like growth factor-I (IGF-I) and IGF-II from neonatal mouse calvaria in organ culture. Endocrinology 1989; 125: 1484-91.
75. Verheijen MH, Defize LH. Parathyroid hormone inhibits mitogen-activated protein kinase activation in osteosarcoma cells via a protein kinase A-dependent pathway. Endocrinology 1995; 136: 3331-7.
76. Watson P, Lazowski D, Han V, Fraher L, Steer B, Hodsman A. Parathyroid hormone restores bone mass and enhances osteoblast insulin-like growth factor I gene expression in ovariectomized rats. Bone 1995; 16: 357-65.
77. Canalis E, Centrella M, Burch W, McCarthy TL. Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J Clin Invest 1989; 83: 60-5.
78. Ishizuya T, Yokose S, Hori M, Noda T, Suda T, Yoshiki S, et al. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J Clin Invest 1997; 99: 2961-70.
79. Harvey AK, Yu XP, Frolik CA, Chandrasekhar S. Parathyroid hormone-(1-34) enhances aggrecan synthesis via an insulin-like growth factor-I pathway. J Biol Chem 1999; 274: 23249-55.
80. Miyakoshi N, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S. Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology 2001; 142: 4349-56.
81. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-76.
82. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95: 3597-602.
83. Hofbauer LC, Heufelder AE. Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 2000; 85: 2355-63.
84. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, et al. Catabolic effects of continuous human PTH (1 - 38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 2001; 142: 4047-54.
85. Onyia JE, Miles RR, Yang X, Halladay DL, Hale J, Glasebrook A, et al. In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J Bone Miner Res 2000; 15: 863-71.
86. Locklin RM, Khosla S, Turner RT, Riggs BL. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem 2003; 89: 180-90.
87. Wronski TJ, Cintron M, Dann LM. Temporal relationship between bone loss and increased bone turnover in ovariectomized rats. Calcif Tissue Int 1988; 43: 179-83.
88. Hough S, Avioli LV, Bergfeld MA, Fallon MD, Slatopolsky E, Teitelbaum SL. Correction of abnormal bone and mineral metabolism in chronic streptozotocin-induced diabetes mellitus in the rat by insulin therapy. Endocrinology 1981; 108: 2228-34.
89. Shires R, Teitelbaum SL, Bergfeld MA, Fallon MD, Slatopolsky E, Avioli LV. The effect of streptozotocin-induced chronic diabetes mellitus on bone and mineral homeostasis in the rat. J Lab Clin Med 1981; 97: 231-40.
90. Weinreb M, Rodan GA, Thompson DD. Osteopenia in the immobilized rat hind limb is associated with increased bone resorption and decreased bone formation. Bone 1989; 10: 187-94.
91. Shen V, Liang XG, Birchman R, Wu DD, Healy D, Lindsay R, et al. Short-term immobilization-induced cancellous bone loss is limited to regions undergoing high turnover and/or modeling in mature rats. Bone 1997; 21: 71-8.
92. Chen MM, Jee WS, Ke HZ, Lin BY, Li QN, Li XJ. Adaptation of cancellous bone to aging and immobilization in growing rats. Anat Rec 1992; 234: 317-34.
93. Lin BY, Jee WS, Chen MM, Ma YF, Ke HZ, Li XJ. Mechanical loading modifies ovariectomy-induced cancellous bone loss. Bone Miner 1994; 25: 199-210.
94. Parfitt AM. Age-related structural changes in trabecular and cortical bone: cellular mechanisms and biomechanical consequences. Calcif Tissue Int 1984; 36: S123-8.
95. Parisien MV, McMahon D, Pushparaj N, Dempster DW. Trabecular architecture in iliac crest bone biopsies: infra-individual variability in structural parameters and changes with age. Bone 1988; 9: 289-95.
96. Wakamatsu E, Sissons HA. The cancellous bone of the iliac crest. Calcif Tissue Res 1969; 4: 147-61.
97. Weinstein RS, Hutson MS. Decreased trabecular width and increased trabecular spacing contribute to bone loss with aging. Bone. 1987; 8: 137-42.
98. Parfitt AM, Mathews CH, Villanueva AR, Kleerekoper M, Frame B, Rao DS. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. J Clin Invest 1983; 72: 1396-409.
99. Garrahan NJ, Mellish RW, Compston JE. A new method for the two-dimensional analysis of bone structure in human iliac crest biopsies. J Microsc 1986; 142: 341-9.
100. Vesterby A, Gundersen HJ, Melsen F. Star volume of marrow space and trabeculae of the first lumbar vertebra: sampling efficiency and biological variation. Bone 1989; 10: 7-13.
101. Vesterby A. Star volume of marrow space and trabeculae in iliac crest: sampling procedure and correlation to star volume of first lumbar vertebra. Bone 1990; 11: 149-55.
102. Hahn M, Vogel M, Pompesius-Kempa M, Delling G. Trabecular bone pattern factor - a new parameter for simple quantification of bone microarchitecture. Bone 1992; 13: 327-30.
103. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003; 18: 1932-41.
104. Shen V, Dempster DW, Birchman R, Xu R, Lindsay R. Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol. J Clin Invest 1993; 91: 2479-87.
105. 3 production in cultured kidney cells. Endocrinology 1981; 108: 733-5.
106. 3-1 alpha-hydroxylase activity in isolated kidney cells of normal and streptozotocin-induced diabetic rats. Calcif Tissue Int 1985; 37: 625-9.
107. Krakauer JC, McKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM. Bone loss and bone turnover in diabetes. Diabetes 1995; 44: 775-82.
108. Okimoto N, Tsurukami H, Okazaki Y, Nishida S, Sakai A, Ohnishi H, et al. Effects of a weekly injection of human parathyroid hormone (1-34) and withdrawal on bone mass, strength, and turnover in mature ovariectomized rats. Bone 1998; 22: 523-31.
109. Turner RT, Evans GL, Cavolina JM, Halloran B, Morey-Holton E. Programmed administration of parathyroid hormone increases bone formation and reduces bone loss in hindlimb-unloaded ovariectomized rats. Endocrinology 1998; 139: 4086-91.
110. 3 or risedronate on endosteal bone remodeling in canine cancellous and cortical bone. J Bone Miner Res 1996; 11: 600-13.
111. Boyce RW, Wronski TJ, Ebert DC, Stevens ML, Paddock CL, Youngs TA, et al. Direct stereological estimation of three-dimensional connectivity in rat vertebrae: effect of estrogen, etidronate and risedronate following ovariectomy. Bone 1995; 16: 209-13.
112. Lane NE, Thompson JM, Strewler GJ, Kinney JH. Intermittent treatment with human parathyroid hormone (hPTH[1-34]) increased trabecular bone volume but not connectivity in osteopenic rats. J Bone Miner Res 1995; 10: 1470-7.
113. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001; 16: 1846-53.
114. Mehta NM, Malootian A, Gilligan JP. Calcitonin for osteoporosis and bone pain. Curr Pharm Design 2003; 9(32): 2659-76.
115. Nemeth FF. Pharmacological regulation of parathyroid hormone secretion. Curr Pharm Design 2002; 8(23): 2077-87.
116. Svensson J. The importance of growth hormone (GH) and GH secretagogues for bone mass and density. Curr Pharm Design 2002; 8(23): 2023-32.